Effects of a Soya-Based Fibre Beverage on Weight and Health in Overweight Adults (SBB-WEIGHTLOSS)
torstai 21. toukokuuta 2026 päivittänyt: Wan Rosli Wan Ishak, Universiti Sains Malaysia
Research on the Effect of Soya-Based Dietary Fibre Beverages (SBB) in Improving Anthropometric Parameters and Biomarker Profiles Among Overweight Students and Staff in Health Campus, Universiti Sains Malaysia, Kelantan
The goal of this intervention study is to evaluate the effect of soya-based dietary fiber beverage (SBB) in overweight adults. The main question it aims to answer is:
Does the SBB effective in improving the weight and metabolic parameters among overweight adults?
Overweight participants will be randomly assigned to intervention or control group for a defined intervention period. The intervention involved the consumption of the SBB beverage powder while allowing participants to maintain their usual meal portions. while the control group will be asked to continue their usual breakfast, lunch, and dinner meals during the study period. Clinical and biochemical parameters will be assessed at baseline and after the intervention period to evaluate potential metabolic changes. Anthropometric and body composition will be recorded. Assessments will include questionnaires related to food frequency (FFQ), food diary, physical activity (IPAQ), satiety and appetite, and defecation behavior.
Tutkimuksen yleiskatsaus
Tila
Valmis
Ehdot
Interventio / Hoito
Yksityiskohtainen kuvaus
Dietary fiber plays a crucial role in weight management by enhancing satiety, reducing caloric intake, and modulating gut microbiota.
Among various fiber sources, soya- based dietary fiber (SBB) is of particular interest due to its combined benefits of soluble and insoluble fiber, plant-based proteins, and bioactive compounds.
Studies have shown that soya proteins and isoflavones contribute to lipid metabolism, insulin sensitivity, and overall weight reduction.
However, there is limited research on the direct impact of soya-based dietary fiber beverages (SBB) on weight loss and metabolic health outcomes.
In this study, the investigators have already developed soya-based dietary fiber beverage (SBB) formulated with soymilk powder, apple mixture powder, and botanical powder.
While the formulation has been completed, its efficacy in improving anthropometric parameters and metabolic profiles among overweight adults remains untested.
Individuals who agree to participate in this study will be divided into two groups: the Control Group and the Intervention Group.
The intervention involves consume two servings of the beverage at least 30 min before each breakfast and teatime every day for 12 weeks, while the control group will be asked to continue their usual breakfast, lunch, and dinner meals during the study period.
Regular consumption of the SBB beverage over three months may lead to significant improvements in metabolic health, including a reduction in body weight, improved body composition, and enhanced satiety response.
Additionally, participants are expected to show positive changes in dietary intake patterns, physical activity levels, and quality of life.
Biomarker analysis will further assess the impact of the intervention on metabolic and inflammatory parameters.
Opintotyyppi
Interventio
Ilmoittautuminen (Todellinen)
42
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.
Opiskelupaikat
-
-
Kelantan
-
Kubang Kerian, Kelantan, Malesia, 16150
- Health Campus, Universiti Sains Malaysia
-
-
Osallistumiskriteerit
Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Aikuinen
Hyväksyy terveitä vapaaehtoisia
Joo
Kuvaus
Inclusion Criteria:
- Staff or students aged 18-50 years
- Participants with BMI 23-30 kg/m2
- Participants physically inactive
- Not having any allergies to any of the known food ingredients, especially milk and soy
- Not on lipid-lowering and oral hypoglycemic drugs
- No kidney diseases
Exclusion Criteria:
- Pregnant or lactating mothers
- Having known chronic disease conditions
- Having a known allergy history for soy and milk or any of the ingredients in the formula.
- History of any type of minor or major surgical procedure in the past 6 months.
- Currently on diet prescriptions or participating in regular physical activity sessions.
- On weight loss drugs or consuming dietary supplements such as protein shakes, whey protein, casein, fruit juices or fiber-based supplements.
Opintosuunnitelma
Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Kokeellinen: Soya-based dietary fibre beverage
The SBB beverage was in powdered form (1 sachet contain 53g of powder), and participants were instructed to prepare the liquid shake by mixing the 1 sachet of the powder with 250 mL of cold water in a shaker that had been provided.
They were asked to consume two servings of the beverage at least 30 min before each breakfast and teatime every day for 12 weeks.
The intervention group was given a sufficiently SBB sachet with a label indicating the ingredients and the preparation method.
The breakfast, lunch, and dinner meals were recommended as normal meals (the meals that they habitually eat).
The intervention involved the consumption of the SBB beverage powder while allowing participants to maintain their usual meal portions.
There was no strict portion control, and participants could continue their habitual eating patterns.
The focus was on incorporating the SBB beverage as part of their daily diet without restricting overall food intake.
|
The intervention consume two servings of the beverage at least 30 min before each breakfast and teatime every day for 12 weeks.
One serving is one sachet (53g) of beverage powder in 250 mL cold water.
There was no strict portion control, and participants could continue their habitual eating patterns.
The focus was on incorporating the SBB beverage as part of their daily diet without restricting overall food intake.
|
|
Ei väliintuloa: Habitual diet
The control group was asked to continue their usual breakfast, lunch, and dinner meals during the study period
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Change in weight (kg)
Aikaikkuna: Baseline, week 4, week 8 and week 12
|
Changes in body weight (kg) from baseline to week 12
|
Baseline, week 4, week 8 and week 12
|
|
Change in body fat percentage (%)
Aikaikkuna: Baseline, week 4, week 8 and week 12
|
Change in body fat percentage (%) from baseline to week 12.
|
Baseline, week 4, week 8 and week 12
|
|
Change in body mass index (BMI) kg/m^2
Aikaikkuna: Baseline, week 4, week 8 and week 12
|
Changes in BMI (kg/m^2) from baseline to week 12. Weight (kg) and height (m) will be measured and combined to report BMI in kg/m²
|
Baseline, week 4, week 8 and week 12
|
|
Change in waist circumference (cm)
Aikaikkuna: Baseline, week 4, week 8 and week 12
|
Change in waist circumference (cm) from baseline to week 12
|
Baseline, week 4, week 8 and week 12
|
|
Change in hip circumference (cm)
Aikaikkuna: Baseline, week 4, week 8 and week 12
|
Changes in hip circumference (cm) from baseline to week 12
|
Baseline, week 4, week 8 and week 12
|
|
Change in body fat mass (kg)
Aikaikkuna: Baseline, week 4, week 8 and week 12
|
Change in body fat mass (kg) from baseline to week 12.
|
Baseline, week 4, week 8 and week 12
|
|
Change in body fat-free mass (kg)
Aikaikkuna: Baseline, week 4, week 8 and week 12
|
Change in body fat-free mass (kg) from baseline to week 12.
|
Baseline, week 4, week 8 and week 12
|
|
Change in visceral fat rating
Aikaikkuna: Baseline, week 4, week 8 and week 12
|
Change in visceral fat rating from baseline to week 12. Visceral Fat Rating from 1 to 12: Indicates a healthy level of visceral fat.
Visceral Fat Rating from 13 to 59: Indicates an excess level of visceral fat.
|
Baseline, week 4, week 8 and week 12
|
|
Change in muscle mass (kg)
Aikaikkuna: Baseline, week 4, week 8 and week 12
|
Change in muscle mass (kg) from baseline to week 12.
|
Baseline, week 4, week 8 and week 12
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Change in blood pressure (mmHg)
Aikaikkuna: Baseline, week 4, week 8 and week 12
|
Change in systolic blood pressure (mmHg) and diastolic blood pressure (mmHg) from baseline to week 12.
|
Baseline, week 4, week 8 and week 12
|
|
Change in total cholesterol (mg/dL)
Aikaikkuna: Baseline and week 12
|
Change in total cholesterol (mg/dL) from baseline to week 12
|
Baseline and week 12
|
|
Change in low-density lipoprotein (LDL) (mg/dL)
Aikaikkuna: baseline and week 12
|
Change in low-density lipoprotein (LDL) (mg/dL) from baseline to week 12
|
baseline and week 12
|
|
Change in high-density lipoprotein (HDL) (mg/dL)
Aikaikkuna: Baseline and week 12
|
Change in high-density lipoprotein (HDL) (mg/dL) from baseline to week 12
|
Baseline and week 12
|
|
Change in triglycerides (mg/dL)
Aikaikkuna: Baseline and week 12
|
Change in triglycerides (mg/dL) from baseline to week 12
|
Baseline and week 12
|
|
Change in total protein (g/L)
Aikaikkuna: Baseline and week 12
|
Change in total protein (g/L) from baseline to week 12
|
Baseline and week 12
|
|
Change in albumin (g/L)
Aikaikkuna: Baseline and week 12
|
Change in albumin (g/L) from baseline to week 12
|
Baseline and week 12
|
|
Change in bilirubin (µmol/L)
Aikaikkuna: Baseline and week 12
|
Change in bilirubin (µmol/L) from baseline to week 12
|
Baseline and week 12
|
|
Change in alkaline phosphatase (ALP) (U/L)
Aikaikkuna: Baseline and week 12
|
Change in alkaline phosphatase (ALP) (U/L) from baseline to week 12
|
Baseline and week 12
|
|
Change in alanine transaminase (ALT) (U/L)
Aikaikkuna: Baseline and week 12
|
Change in alanine transaminase (ALT) (U/L) from baseline to week 12
|
Baseline and week 12
|
|
Change in aspartate aminotransferase (AST) (U/L)
Aikaikkuna: Baseline and week 12
|
Change in aspartate aminotransferase (AST) (U/L)
|
Baseline and week 12
|
|
Change in gamma-glutamyl transferase (GGT) (U/L)
Aikaikkuna: Baseline and week 12
|
Change in gamma-glutamyl transferase (GGT) (U/L) from baseline to week 12
|
Baseline and week 12
|
|
Change in urea (mmol/L)
Aikaikkuna: Baseline and week 12
|
Change in urea (mmol/L) from baseline to week 12
|
Baseline and week 12
|
|
Change in estimated Glomerular Filtration Rate (eGFR) (mL/min)
Aikaikkuna: Baseline and week 12
|
Change in estimated Glomerular Filtration Rate (eGFR) (mL/min) from baseline to week 12
|
Baseline and week 12
|
|
Change in creatinine (µmol/L)
Aikaikkuna: Baseline and week 12
|
Change in creatinine (µmol/L) from baseline to week 12
|
Baseline and week 12
|
|
Change in Interleukin-6 (IL-6) (pg/mL)
Aikaikkuna: Baseline and week 12
|
Change in IL-6 (pg/mL) and C-reactive protein from baseline to week 12
|
Baseline and week 12
|
|
Change in C-reactive protein (mg/mL)
Aikaikkuna: Baseline and week 12
|
Change in C-reactive protein (mg/mL) from baseline to week 12.
|
Baseline and week 12
|
Muut tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
Physical activity level (MET-minutes/week)
Aikaikkuna: Baseline and week 12
|
Physical activity was assessed using the Malay version of the International Physical Activity Questionnaire (IPAQ).
The data was processed according to the official IPAQ scoring protocol.
The results are reported as continuous scores expressed in Metabolic Equivalent of Task (MET)-minutes per week.
Higher scores indicate a greater volume of physical activity expenditure.
|
Baseline and week 12
|
|
Change in Diet
Aikaikkuna: Baseline, week 4 and week 12
|
Change in average daily diet intake, assessed using 24-hour recalls and 3-day food records.
Dietary data were entered into Nutritionist Pro™ software (Axxya Systems, USA) to estimate mean daily energy and nutrient intake, including macronutrients and dietary fibre.
For food items that are not available in the Malaysian Nutrient Composition of Foods, the USDA nutrient database was referred.
For mixed dishes that were not available in the database, local recipes were entered into the software.
|
Baseline, week 4 and week 12
|
|
Change in appetite
Aikaikkuna: Baseline, week 4 and week 12
|
Subjective appetite sensations were assessed using an eleven-point numerical rating scale (NRS), with anchors at 0 ("not at all") and 10 ("very much"), to evaluate hunger, fullness, desire to eat, thirst, and prospective food consumption.
Participants completed the questionnaire before and after breakfast, lunch, and dinner at each study time point (pre, week 4, and post).
For analysis and comparability with conventional visual analogue scale (VAS) methods, NRS scores were linearly transformed to a 0-100 scale by multiplying each value by 10.
|
Baseline, week 4 and week 12
|
|
Frequency of defecation
Aikaikkuna: Baseline, week 4 and week 12
|
Frequency of defecation will be assessed using the Questionnaire of Regularity of Defecation Behavior.
Participants will report the frequency of bowel movements categorized as 1 time/day, more than 1 time/day, 2-3 times/week, or 4-5 times/week.
|
Baseline, week 4 and week 12
|
|
Time of defecation
Aikaikkuna: Baseline, week 4 and week 12
|
Time of defecation will be assessed using the Questionnaire of Regularity of Defecation Behavior.
Participants will report the usual timing of bowel movements within specified time intervals over a 24-hour period.
|
Baseline, week 4 and week 12
|
|
Stool consistency
Aikaikkuna: Baseline, week 4 and week 12
|
Stool consistency will be assessed using the Bristol Stool Form Scale, a 7-point scale ranging from Type 1 (hard lumps indicating constipation) to Type 7 (watery stool indicating diarrhea).
Types 3 and 4 indicate normal stool consistency.
|
Baseline, week 4 and week 12
|
|
Stool color
Aikaikkuna: Baseline, week 4 and week 12
|
Stool color will be assessed using the Questionnaire of Regularity of Defecation Behavior.
Participants will report stool color categorized as brown, yellow, black, red, green, or blue.
|
Baseline, week 4 and week 12
|
|
Stool amount per defecation
Aikaikkuna: Baseline, week 4 and week 12
|
Amount of stool per defecation will be assessed using the Questionnaire of Regularity of Defecation Behavior and categorized as 1-2 stools, 3-4 stools, or more than 5 stools.
|
Baseline, week 4 and week 12
|
|
Feces odor
Aikaikkuna: Baseline, week 4 and week 12
|
Feces odor will be assessed using the Questionnaire of Regularity of Defecation Behavior and categorized as regular or irregular.
|
Baseline, week 4 and week 12
|
|
Ease of defecation
Aikaikkuna: Baseline, week 4 and week 12
|
Ease of defecation will be assessed using the Questionnaire of Regularity of Defecation Behavior and categorized as easy or hard defecation.
|
Baseline, week 4 and week 12
|
|
Effect on quality of life
Aikaikkuna: Baseline and week 12
|
The quality of life outcome will be assessed using the World Health Organization Quality of Life-BREF (WHOQOL-BREF) questionnaire, a 26-item instrument evaluating four domains: physical health, psychological health, social relationships, and environment.
Each domain score ranges from 0 to 100, with higher scores indicating better quality of life.
Assessments will be conducted at baseline (pre-intervention) and after completion of the intervention (post-intervention).
|
Baseline and week 12
|
Yhteistyökumppanit ja tutkijat
Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.
Sponsori
Tutkijat
- Päätutkija: Wan Rosli Wan Ishak, PhD, School of Health Sciences, Universiti Sains Malaysia, Health Campus, 16150 Kubang Kerian, Kelantan, Malaysia
Opintojen ennätyspäivät
Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan julkisella verkkosivustolla.
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Maanantai 30. kesäkuuta 2025
Ensisijainen valmistuminen (Todellinen)
Maanantai 1. joulukuuta 2025
Opintojen valmistuminen (Todellinen)
Maanantai 1. joulukuuta 2025
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Perjantai 15. toukokuuta 2026
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Torstai 21. toukokuuta 2026
Ensimmäinen Lähetetty (Todellinen)
Perjantai 29. toukokuuta 2026
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Perjantai 29. toukokuuta 2026
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Torstai 21. toukokuuta 2026
Viimeksi vahvistettu
Perjantai 1. toukokuuta 2026
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- USM/JEPeM/KK/24111003
- R504-LR-GAL007-0000000410-M201 (Muu apuraha/rahoitusnumero: MELILEA SDN BHD)
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
EI
IPD-suunnitelman kuvaus
Individual participant data will not be made publicly available to protect participant confidentiality and comply with institutional and ethical regulations governing clinical research data.
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Ei
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Ei
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .